1
|
Ansell SM, Bröckelmann PJ, Keudell G, Lee HJ, Santoro A, Zinzani PL, Collins GP, Cohen JB, Boer JP, Kuruvilla J, Savage KJ, Trneny M, Provencio M, Jaeger U, Willenbacher W, Swanink R, Sacchi M, Shipp MA, Engert A, Armand P. NIVOLUMAB FOR RELAPSED OR REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL) AFTER AUTOLOGOUS TRANSPLANTATION: 5‐YEAR OVERALL SURVIVAL FROM THE PHASE 2 CHECKMATE 205 STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.74_2879] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- S. M. Ansell
- Mayo Clinic Division of Hematology Rochester Minnesota USA
| | - P. J. Bröckelmann
- University Hospital of Cologne Department of Internal Medicine Cologne Germany
| | - G. Keudell
- Memorial Sloan Kettering Cancer Center Department of Hematology New York New York USA
| | - H. J. Lee
- University of Texas MD Anderson Cancer Center Department of Lymphoma and Myeloma Houston Texas USA
| | - A. Santoro
- Humanitas University Humanitas Cancer Center Rozzano Milan Italy
| | - P. L. Zinzani
- University of Bologna Institute of Hematology L. e A. Seràgnoli Bologna Italy
| | - G. P. Collins
- Churchill Hospital Oxford Cancer and Haematology Centre Oxford UK
| | - J. B. Cohen
- Emory University Winship Cancer Institute Atlanta Georgia USA
| | - J. P. Boer
- Antoni van Leeuwenhoek Hospital Netherlands Cancer Institute Amsterdam Netherlands
| | - J. Kuruvilla
- University of Toronto and Princess Margaret Cancer Centre Division of Medical Oncology and Hematology Toronto Canada
| | - K. J. Savage
- BC Cancer Department of Medical Oncology Vancouver Canada
| | - M. Trneny
- Charles University in Prague and General University Hospital in Prague Department of Haematology Prague Czech Republic
| | - M. Provencio
- Hospital Universitario Puerta de Hierro Department of Medical Oncology Madrid Spain
| | - U. Jaeger
- Medical University of Vienna Clinical Department for Hematology and Hemostaseology Vienna Austria
| | - W. Willenbacher
- Innsbruck Medical University Department of Internal Medicine V Innsbruck Austria
| | - R. Swanink
- Bristol Myers Squibb Global Biometrics and Data Sciences Braine l’Alleud Belgium
| | - M. Sacchi
- Bristol Myers Squibb, Global Drug Development Princeton New Jersey USA
| | - M. A. Shipp
- Dana‐Farber Cancer Institute Department of Medical Oncology Boston Massachusetts USA
| | - A. Engert
- University Hospital of Cologne Department of Internal Medicine Cologne Germany
| | - P. Armand
- Dana‐Farber Cancer Institute Department of Medical Oncology Boston Massachusetts USA
| |
Collapse
|